Overexpression of IGF2BP3 as a Potential Oncogene in Ovarian Clear Cell Carcinoma.

Abstract

Ovarian Clear Cell Carcinoma (OCCC) displays distinctive clinical and molecular characteristics and confers the worst prognosis among all ovarian carcinoma histotypes when diagnosed at advanced stage, because of the lack of effective therapy. IGF2BP3 is an RNA binding protein that modulates gene expression by post-transcriptional action. In this study, we investigated the roles of IGF2BP3 in the progression of OCCC. We used 328 OCCCs from the AOVT (the Alberta Ovarian Tumor Type study) and the COEUR (the Canadian Ovarian Experimental Unified Resource) cohorts to elucidate the associations between IGF2BP3 expression and clinicopathological parameters, with positive IGF2BP3 expression defined as diffuse block staining, being more frequently observed at stage III (P = 0.0056) and significantly associated with unfavorable overall survival (HR = 1.59, 95% CI 1.09-2.33) in multivariate analysis. IGF2BP3 mRNA gene expression was markedly increased in OCCC cell lines compared to normal tissues such as ovarian surface epithelium. We chose two IGF2BP3-overexpressing cell lines ES2 and OVMANA for in vitro and in vivo knockdown experiments. The proliferation and viability of both cell lines were significantly inhibited by two IGF2BP3 siRNAs and similar suppression was observed in cell migration and invasion by Wound Healing and Transwell assays. The percentage of apoptotic cancer cells was enhanced by both IGF2BP3 siRNAs. In vivo experiments showed significantly reduced sizes of tumors when treated with IGF2BP3 siRNA compared to controls. Furthermore, cancer metastasis-indicators MMP2 and MMP9 proteins were down-regulated. In conclusion, our study shows that IGF2BP3 expression is a promising biomarker for prognostication of women diagnosed with OCCC with multiple effects on key cell functions, supporting its role as an important cellular regulator with potential oncogenic activity, and as a potential target for future intervention strategies.

• Authors: Huidi Liu, Zheng Zeng, Mitra Afsharpad, Caiji Lin, Siwen Wang, Hao Yang, Shuhong Liu, Linda E Kelemen, Wenwen Xu, Wenqing Ma, Qian Xiang, Emilio Mastriani, Pengfei Wang, Jiali Wang, Shu-Lin Liu, Randal N Johnston, Martin Köbel
• Journal: Frontiers in oncology (Front Oncol) Vol. 9 Pg. 1570 ( 2019) ISSN: 2234-943X [Print] Switzerland
• PMID: 32083017 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Liu, Zeng, Afsharpad, Lin, Wang, Yang, Liu, Kelemen, Xu, Ma, Xiang, Mastriani, Wang, Wang, Liu, Johnston and Köbel.